Evidence map›Paper›PMID 36271362›Full record

ArticleBMC infectious diseases2022

Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia.

Yanling Deng, Lin Chen, Mingrui Yue, Xiaobo Huang, Yang Yang, Hua Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026
    Review
  3. The Mortality of Colistin MonotherapyInfection & chemotherapy · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Molecular mechanisms of tigecycline-resistance amongFrontiers in cellular and infection microbiology · 2024
    Review
  8. Article
  9. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yanling DengDepartment of Respiratory and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Lin ChenDepartment of Respiratory and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. chenlinhx@med.uestc.edu.cn.
Mingrui YueDepartment of Intensive Care Unit, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xiaobo HuangDepartment of Intensive Care Unit, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yang YangDepartment of Respiratory and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Hua YuChinese Academy of Sciences Sichuan Translational Medicine Research Hospital, 610072, Chengdu, China.
University of Electronic Science and Technology of China · CN

Funding

Department of Science and Technology of Sichuan Province 2021YFS0373
6 · The paper itself

Abstract

backgroundThe purpose of this study was to review the treatment plan of patients with multidrug-resistant Acinetobacter baumannii (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen.

methodsWe collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed.

resultsThe mortality rate was high for those aged > 75 years (p = 0.001). Patients who underwent invasive catheter placement (p < 0.001) and mechanical ventilation (p = 0.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (p < 0.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (p < 0.001), and high-dose sulbactam (> 3 g/day) might be better than low-dose sulbactam (≤ 3 g/day).

conclusionReducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Infective AgentsPneumoniaAnti-Bacterial AgentsCarbapenemsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsRetrospective StudiesSulbactamTigecyclineAnti-Bacterial AgentsAnti-Infective AgentsCarbapenemsSulbactamTigecyclineCarbapenem-resistant Acinetobacter baumannii(CRAB)Intensive care unitMulti-drug resistant Acinetobacter baumannii (MDR-AB)Severe pneumonia

Identifiers

PMID36271362
PMCPMC9585752
OpenAlexW4306980334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.